Meeting
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
Authors
Hideaki Bando
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Hideaki Bando , Hironaga Satake , Daisuke Kotani , Tetsuya Hamaguchi , Manabu Shiozawa , Taro Ikumoto , Yoshihiro Okita , Toshiki Masuishi , Yoshinori Kagawa , Hisateru Yasui , Eiji Oki , Yoshito Komatsu , Hiroya Taniguchi , Kei Muro , Masahito Kotaka , Kentaro Yamazaki , Toshihiro Misumi , Takayuki Yoshino , Takeshi Kato , Akihito Tsuji
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT04097444
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3565)
DOI
10.1200/JCO.2023.41.16_suppl.3565
Abstract #
3565
Poster Bd #
265
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment.
First Author: Akihito Tsuji
Poster
2014 ASCO Annual Meeting
STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Johanna C. Bendell
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang
Poster
2021 Gastrointestinal Cancers Symposium
Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
First Author: Takanori Watanabe